Published in Vaccine Weekly, January 12th, 2000
In addition, IDM has also become Medarex's first partner for CTLA-4 Blockade technology to enhance cancer vaccines. IDM intends to pursue an anti-CTLA-4 approach in conjunction with its proprietary DendritophagesTM as a cellular vaccine for the treatment of melanoma and prostate cancers.
"Medarex has a unique platform of powerful antibody technologies," stated Jean-Loup Romet-Lemonne, IDM. "This synergistic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly